|
CONSUMER NEWS RECALLS COMPLAINT FORM SCAM ALERTS |
| Small Claims Guide | Class Actions | Lemon Law | FAQ | Resources | Newsletters | Spanish | |
|
|
![]() |
FDA Approves New Treatment for Diabetes |
|||||
|
October 18, 2006
Patients will use the drug, in addition to diet and exercise, to improve blood sugar levels to control type 2 diabetes. Junuvia may be used alone or in combination with two other commonly prescribed oral diabetes medications, metformin or a PPAR agonist, when either of these drugs alone, along with diet and exercise, don't provide adequate blood sugar control. "For the millions of Americans with type 2 diabetes, who continue to have inadequate blood sugar control, the approval of Januvia marks an important advance in the fight against diabetes," said Dr. Steven Galson, Director of FDA's Center for Drug Evaluation and Research. "We now have another new option that treats the disease in an entirely new way that can be added to existing treatment regimens to help patients gain more control over their blood sugar levels." Type 2 diabetes is the most common form of the disease, accounting for about 90 percent to 95 percent of all diagnosed cases of diabetes. Type 2 diabetes cases have surged in recent years, due in part to the dramatic rise in obesity. In type 2 diabetes, the body does not produce enough insulin or the cells ignore the insulin. Insulin is necessary to take sugar, the basic fuel for cells, from the blood into the cells. Over time, high blood sugar levels can increase the risk for serious complications, including heart disease, blindness, nerve damage, and kidney damage. Januvia prolongs the activity of proteins that increase the release of insulin after blood sugar rises, such as after a meal. Januvia does this by blocking an enzyme which breaks down these proteins, leading to better blood sugar control. Januvia was examined in a total of 2,719 patients with type 2 diabetes, in studies lasting from 12 weeks to more than a year. These studies demonstrated improved blood sugar control when Januvia was used alone or in patients not satisfactorily managed with metformin or a PPAR agonist. The most common side effects in clinical studies were upper respiratory tract infection, sore throat, and diarrhea. Januvia is manufactured by Merck and Co. Report Your Experience
|
|||||
Back to the top | |
||||||
Advertisement
|
Home |
Rogues Gallery |
Good Guys |
Complaint Form |
News |
Recalls |
Search |
Video |
FAQ |
|
Terms of Use Your use of this site constitutes acceptance of the Terms of Use
Copyright © 2003-2008 ConsumerAffairs.com Inc. All Rights Reserved. |